Teva filed a new drug application to market a generic version of Actonel, the osteoporosis drug in the U.S., asserting that the Procter & Gamble patent wasn’t valid. However, the validity of the patent was upheld in a ruling by the U.S. District Court of Delaware which rejected Teva’s claims and gives Procter & Gamble Co. the exclusive right to market Actonel in the States.
Teva Pharmaceutical Industries Ltd. (TEVA) announced on Friday that it will appeal the decision.
